Bervin Bouani

Bervin Bouani has spent their career in the medical and pharmaceutical industries, with a focus on innovative startups. Bervin is currently a board member at Germitec SAS, a French company that specializes in developing treatments for Alzheimer's and other neurodegenerative diseases. Prior to this, they were CEO of Mablink Bioscience, a biotech startup that developed monoclonal antibodies for the treatment of cancer. Before that, they were CEO of AbolerIS Pharma, a pharmaceutical company that developed drugs for the treatment of rare diseases. Bervin has also held leadership positions at InnoSkel, Pixee Medical, Dessintey, CarThera, BrainEver, and Turenne Capital.

Bervin Bouani pursued a Master II in Capital Markets & Corporate Finance at Université catholique de Lille.